OBJECTIVE: To assess the effect of HIV care (including highly active antiretroviral therapy if eligible) on neurodevelopment. DESIGN: Prospective cohort study. METHODS: Motor and mental development of 35 HIV-infected children (aged 18-71 months) was assessed at entry into care and after 6 and 12 months using age-appropriate tools. Developmental trajectory was compared with 35 HIV-uninfected, affected, and 90 control children using linear mixed-effects models. Effects of age (<or= or >29 months) and timing of entry into care (before or after highly active antiretroviral therapy eligibility) were explored in secondary analyses. RESULTS: At baseline, HIV-infected children had the lowest, control children the highest, and HIV-uninfected affected children intermediate mean developmental scores. After 1 year of care, HIV-infected children achieved mean motor and cognitive scores that were similar to HIV uninfected, affected children although lower compared with control children. Overall, HIV-infected children experienced accelerated motor development but similar gains in cognitive development compared with control children. Exploratory analyses suggest that younger children and those presenting early may experience accelerated greater gains in development. CONCLUSIONS: HIV-infected children accessing care experience improved motor development, and may, if care is initiated at a young age or an early stage of the disease, also experience gains in cognitive development.
OBJECTIVE: To assess the effect of HIV care (including highly active antiretroviral therapy if eligible) on neurodevelopment. DESIGN: Prospective cohort study. METHODS: Motor and mental development of 35 HIV-infectedchildren (aged 18-71 months) was assessed at entry into care and after 6 and 12 months using age-appropriate tools. Developmental trajectory was compared with 35 HIV-uninfected, affected, and 90 control children using linear mixed-effects models. Effects of age (<or= or >29 months) and timing of entry into care (before or after highly active antiretroviral therapy eligibility) were explored in secondary analyses. RESULTS: At baseline, HIV-infectedchildren had the lowest, control children the highest, and HIV-uninfected affected children intermediate mean developmental scores. After 1 year of care, HIV-infectedchildren achieved mean motor and cognitive scores that were similar to HIV uninfected, affected children although lower compared with control children. Overall, HIV-infectedchildren experienced accelerated motor development but similar gains in cognitive development compared with control children. Exploratory analyses suggest that younger children and those presenting early may experience accelerated greater gains in development. CONCLUSIONS:HIV-infectedchildren accessing care experience improved motor development, and may, if care is initiated at a young age or an early stage of the disease, also experience gains in cognitive development.
Authors: Nicholas Blanchette; Mary Lou Smith; Susan King; Alda Fernandes-Penney; Stanley Read Journal: Dev Neuropsychol Date: 2002 Impact factor: 2.253
Authors: L G Epstein; L R Sharer; J M Oleske; E M Connor; J Goudsmit; L Bagdon; M Robert-Guroff; M R Koenigsberger Journal: Pediatrics Date: 1986-10 Impact factor: 7.124
Authors: Cynthia McCoig; Maria Mercedes Castrejón; Elizabeth Castaño; Onix De Suman; Carmen Báez; Wilfrido Redondo; Daniel McClernon; Susan Danehower; E Randall Lanier; Carol Richardson; Amy Keller; Seth Hetherington; Xavier Sáez-Llorens; Octavio Ramilo Journal: J Pediatr Date: 2002-07 Impact factor: 4.406
Authors: P A Pizzo; J Eddy; J Falloon; F M Balis; R F Murphy; H Moss; P Wolters; P Brouwers; P Jarosinski; M Rubin Journal: N Engl J Med Date: 1988-10-06 Impact factor: 91.245
Authors: Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre Journal: N Engl J Med Date: 2008-11-20 Impact factor: 91.245
Authors: Shirin Heidari; Lynne M Mofenson; Charlotte V Hobbs; Mark F Cotton; Richard Marlink; Elly Katabira Journal: J Acquir Immune Defic Syndr Date: 2012-02-01 Impact factor: 3.731
Authors: Theodore D Ruel; Michael J Boivin; Hannah E Boal; Paul Bangirana; Edwin Charlebois; Diane V Havlir; Philip J Rosenthal; Grant Dorsey; Jane Achan; Carolyne Akello; Moses R Kamya; Joseph K Wong Journal: Clin Infect Dis Date: 2012-02-04 Impact factor: 9.079
Authors: Kevin Robertson; Jeff Liner; James Hakim; Jean-Louis Sankalé; Igor Grant; Scott Letendre; David Clifford; Amadou Gallo Diop; Assan Jaye; Georgette Kanmogne; Alfred Njamnshi; T Dianne Langford; Tufa Gemechu Weyessa; Charles Wood; Mwanza Banda; Mina Hosseinipour; Ned Sacktor; Noeline Nakasuja; Paul Bangirana; Robert Paul; John Joska; Joseph Wong; Michael Boivin; Penny Holding; Betsy Kammerer; Annelies Van Rie; Prudence Ive; Avindra Nath; Kathy Lawler; Clement Adebamowo; Walter Royal; Jeymohan Joseph Journal: J Neurovirol Date: 2010-05 Impact factor: 2.643
Authors: Stanzi M le Roux; Kirsten A Donald; Kirsty Brittain; Tamsin K Phillips; Allison Zerbe; Kelly K Nguyen; Andrea Strandvik; Max Kroon; Elaine J Abrams; Landon Myer Journal: AIDS Date: 2018-08-24 Impact factor: 4.177
Authors: Heena Brahmbhatt; Michael Boivin; Victor Ssempijja; Joseph Kagaayi; Godfrey Kigozi; David Serwadda; Avy Violari; Ronald H Gray Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731
Authors: Itziar Familiar; Shalean M Collins; Alla Sikorskii; Horacio Ruisenor-Escudero; Barnabas Natamba; Paul Bangirana; Elizabeth M Widen; Daniel Achidri; Harriet Achola; Daniel Onen; Michael Boivin; Sera L Young Journal: J Acquir Immune Defic Syndr Date: 2018-03-01 Impact factor: 3.731
Authors: Michael J Boivin; Linda Barlow-Mosha; Miriam C Chernoff; Barbara Laughton; Bonnie Zimmer; Celeste Joyce; Mutsa Bwakura-Dangarembizi; Mmule Ratswana; Nasreen Abrahams; Lee Fairlie; Hermien Gous; Portia Kamthunzi; Katie McCarthy; Itziar Familiar-Lopez; Patrick Jean-Phillippe; Joan Coetzee; Avy Violari; Mark F Cotton; Paul E Palumbo Journal: AIDS Date: 2018-01-14 Impact factor: 4.177
Authors: Jadrana T F Toich; Paul A Taylor; Martha J Holmes; Suril Gohel; Mark F Cotton; Els Dobbels; Barbara Laughton; Francesca Little; Andre J W van der Kouwe; Bharat Biswal; Ernesta M Meintjes Journal: Front Hum Neurosci Date: 2018-01-11 Impact factor: 3.169
Authors: Megan S McHenry; Carole I McAteer; Eren Oyungu; Brenna C McDonald; Chris B Bosma; Philani B Mpofu; Andrew R Deathe; Rachel C Vreeman Journal: Pediatrics Date: 2018-02 Impact factor: 7.124